title: Human polymorphonuclear neutrophils specifically recognize and kill cancerous cells.
abstract: Polymorphonuclear neutrophils (PMNs), the main effectors of the innate immune system, have rarely been considered as an anticancer therapeutic tool. However, recent investigations using animal models and preliminary clinical studies have highlighted the potential antitumor efficacy of PMNs. In the current study, we find that PMNs from some healthy donors naturally have potent cancer-killing activity against 4 different human cancer cell lines. The killing activity appears to be cancer cell-specific since PMNs did not kill primary normal epithelial cells or an immortalized breast epithelial cell line. Transfecting the immortalized mammary cells with plasmids expressing activated forms of the rat sarcoma viral oncogene homolog (Ras) and teratocarcinoma oncogene 21 (TC21) oncogenes was sufficient to provoke aggressive attack by PMNs. However, transfection with activated Ras-related C3 botulinum toxin substrate (Rac1) was ineffective, suggesting specificity in PMN-targeting of neoplastic cells. Furthermore, PMNs from lung cancer patients were also found to exhibit relatively poor cancer-killing activity compared to the cytolytic activity of the average healthy donor. Taken together, our results suggest that PMN-based treatment regimens may represent a paradigm shift in cancer immunotherapy that may be easily introduced into the clinic to benefit a subset of patients with PMN-vulnerable tumors.
authors.affiliation: Tumor Immunobiology Program; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA ; Division of Hematology/Oncology; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA.
authors.forename: Jun
authors.initials: J
authors.lastname: Yan
authors.affiliation: Division of Hematology/Oncology; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA.
authors.forename: Goetz
authors.initials: G
authors.lastname: Kloecker
authors.affiliation: Tumor Immunobiology Program; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA.
authors.forename: Chris
authors.initials: C
authors.lastname: Fleming
authors.affiliation: Department of Cardiovascular Thoracic Surgery; University of Louisville ; Louisville, KY USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Bousamra
authors.affiliation: Tumor Immunobiology Program; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA.
authors.forename: Richard
authors.initials: R
authors.lastname: Hansen
authors.affiliation: Tumor Immunobiology Program; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA.
authors.forename: Xiaoling
authors.initials: X
authors.lastname: Hu
authors.affiliation: Tumor Immunobiology Program; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA.
authors.forename: Chuanlin
authors.initials: C
authors.lastname: Ding
authors.affiliation: Tumor Immunobiology Program; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA.
authors.forename: Yihua
authors.initials: Y
authors.lastname: Cai
authors.affiliation: Division of Hematology/Oncology; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA.
authors.forename: Dong
authors.initials: D
authors.lastname: Xiang
authors.affiliation: Division of Hematology/Oncology; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA ; Molecular Targets Program; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA.
authors.forename: Howard
authors.initials: H
authors.lastname: Donninger
authors.affiliation: Division of Hematology/Oncology; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA ; Molecular Targets Program; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA.
authors.forename: John W
authors.initials: JW
authors.lastname: Eaton
authors.affiliation: Division of Hematology/Oncology; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA ; Molecular Targets Program; James Graham Brown Cancer Center; Department of Medicine; University of Louisville ; Louisville, KY USA ; Department of Pharmacology and Toxicology; University of Louisville ; Louisville, KY USA.
authors.forename: Geoffrey J
authors.initials: GJ
authors.lastname: Clark
keywords: BEN, benign ethnic neutropenia; DBL, proto-oncogene DBL; DPI, diphenyleneiodonium; E:T, effector:target; G-CSF, granulocyte-colony stimulating factor; GM-CSF, granulocyte macrophage-colony stimulating factor; GVHD, graft-versus-host disease; H-Ras, Harvey rat sarcoma viral oncogene homolog; MEK, mitogen-activated protein kinase kinase; NADPH, nicotinamide adenine dinucleotide phosphate; NBT, nitroblue tetrazolium; NSCLC, non-small cell lung carcinoma; PI3 kinase, phosphoinositide 3-kinase; PMN, polymorphonuclear neutrophils; ROS, reactive oxygen species; Rac1, Ras-related C3 botulinum toxin substrate 1; RhoA, Ras homolog family member A; TC-21, teratocarcinoma oncogene TC21; TGFβ, transforming growth factor; cytotoxicity; mAb, monoclonal antibody; mTOR, mammalian target of rapamycin; neutrophils; oncogene; tumor cells